Norwest Bank

Northwest Biotherapeutics is a clinical-stage biotechnology company focused on developing personalized cancer vaccines using its proprietary DCVax® dendritic cell platform. The company's lead product candidate, DCVax-L, is designed to treat glioblastoma multiforme (GBM) by utilizing a patient's own dendritic cells primed with tumor lysates to trigger a broad immune response. Northwest Biotherapeutics has completed a large Phase 3 trial for DCVax-L in newly diagnosed and recurrent GBM, reporting significant extensions in median overall survival compared to historical controls. The company is also developing DCVax-Direct for inoperable solid tumors, which involves direct injection of dendritic cells into tumor sites. Northwest Biotherapeutics continues to work toward regulatory approvals and the commercialization of its personalized immunotherapy approach globally.